康复机器人研发商Bioxtreme获得战略融资，并推出Plaxtreme加速神经康复创新-动脉网

Bioxtreme Announces Strategic Investment Led by Serra Holding | Amperos Health Secures $16M Investment

Healthcare IT Today 等信源发布 2026-04-28 21:06



可切换为仅中文







Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past

查看今天展示的公司，它们最近完成了一轮融资，并务必查看过去的完整列表

healthcare IT fundings

医疗IT基金

。

Bioxtreme Announces Strategic Investment Led by Serra Holding and Introduces Plaxtreme to Accelerate Neurorehabilitation Innovation

Bioxtreme宣布由Serra Holding领投的战略投资，并推出Plaxtreme以加速神经康复创新。

Leadership Expansion Across the U.S. and Europe Supports Global Growth of Next-Generation Neurorehabilitation Robotics

美国和欧洲的领导力扩展支持了下一代神经康复机器人技术的全球增长

Bioxtreme

生物极限

, an innovator in neurorehabilitation technologies leveraging its proprietary error augmentation approach to accelerate motor recovery, today announced a new strategic investment led by Serra Holding, a family office focused on hands-on investment and operational support across the healthcare sector, including hospitals, mental health institutions, and medtech companies.

，一家利用其专有的错误增强方法加速运动功能恢复的神经康复技术领域的创新者，今天宣布了一项由塞拉控股（Serra Holding）领投的新战略投资。塞拉控股是一家家族办公室，专注于医疗保健领域的实践型投资和运营支持，涵盖医院、心理健康机构和医疗技术公司。

This investment brings the company’s total funding to $15 million to date, accelerating Bioxtreme’s global expansion, strengthening operations in the United States and Europe, and supporting the launch of Plaxtreme, the company’s advanced robotic rehabilitation device engineered to drive neuroplasticity and accelerate motor skill recovery in individuals with neurological conditions..

这项投资使该公司的总融资额达到1500万美元，加速了Bioxtreme的全球扩张，加强了其在美国和欧洲的业务，并支持了Plaxtreme的推出。Plaxtreme是该公司先进的机器人康复设备，旨在推动神经可塑性并加速神经系统疾病患者的运动技能恢复。

Plaxtreme is designed to address the restoration of functional hand movement. Combining precision robotics, immersive virtual environments, and Bioxtreme’s proprietary error augmentation technology, Plaxtreme restores grasp and release while accelerating recovery and improving functional outcomes for users.

Plaxtreme 旨在恢复手部功能运动。通过结合精密机器人技术、沉浸式虚拟环境以及 Bioxtreme 的专有错误增强技术，Plaxtreme 能够恢复抓握和释放能力，同时加速康复并改善用户的功能性结果。

Key capabilities include:.

关键能力包括：。

Patented Error Augmentation Technology –

专利错误增强技术 –

Amplifies movement errors to trigger the brain’s natural adaptive responses, accelerating motor learning and improving movement accuracy

放大运动错误以触发大脑的自然适应反应，加速运动学习并提高运动准确性。

Personalized Adaptive, AI-Based Learning

个性化自适应的基于人工智能的学习

– AI analyzes movement performance in real time, adjusting subtle force demands and therapy parameters; continuously adapts to support progressive learning

– 人工智能实时分析运动表现，调整细微的力度要求和治疗参数；持续适应以支持渐进式学习。

Supination and Pronation Training-

旋后与旋前训练-

Supports natural forearm rotation for functional movement, improves coordination for daily tasks; functional, ADL-based activities in an interactive, 3D environment; gamified tasks drive engagement and high repetition practice

支持前臂自然旋转以实现功能性运动，提高日常任务的协调性；在互动的3D环境中进行基于日常生活活动（ADL）的功能性活动；游戏化任务提升参与度和高重复性练习。

Adaptive Feedback Driven Rehabilitation –

自适应反馈驱动康复 –

Real-time, visual feedback supports continuous progress; automatically adapts difficulty to the patient’s ability

实时、视觉反馈支持持续进展；自动适应患者的能力调整难度

Designed for Smooth, OT Workflows

专为流畅的 OT 工作流程设计

– Quick setup with no complex calibration, and seamless left/right and transition; convenient hand positioning for efficient clinical use

- 快速设置，无需复杂校准，左右和过渡无缝衔接；方便手部定位，提高临床使用效率

Bioxtreme’s portfolio also includes Dextreme, an advanced robotic rehabilitation system for upper-limb recovery that also applies adaptive error augmentation forces to accelerate motor learning and restore functional independence…

Bioxtreme的产品组合还包括Dextreme，这是一款用于上肢康复的先进机器人康复系统，该系统还应用了适应性错误增强力量来加速运动学习并恢复功能独立性。

Full release here

完整发布在这里

, originally announced April 21st, 2026.

，最初宣布于2026年4月21日。

Amperos Health Secures $16M Investment as it Launches Industry’s First AI-Native Denial Management and Revenue Recovery Platform

安培健康公司在推出行业首个AI原生拒绝管理与收入恢复平台之际，获得了1600万美元的投资。

Helping Providers Resolve Denials Five Times Faster and Cut Denial Rates by 70%

帮助供应商解决拒绝问题的速度快五倍，并将拒绝率降低70%

Amperos Health

安培健康

, the first insurance revenue recovery partner capable of working denials end-to-end entirely with AI, announced today that it has closed a $16 million Series A funding round, led by Bessemer Venture Partners, with participation from Uncork Capital and Neo.

，首家能够完全通过人工智能端到端处理拒绝索赔的保险收入追回合作伙伴，今天宣布已完成1600万美元的A轮融资，该轮融资由Bessemer Venture Partners领投，Uncork Capital和Neo参与。

The raise comes as Amperos launches the industry’s first AI-native denial management and revenue recovery solution for healthcare providers. Amperos’ agentic capabilities provide end-to-end denial and collection automation, while a team of subject matter experts provides judgment and expertise for complex and difficult-to-recover claims.

此次融资正值Amperos推出医疗保健行业首个原生人工智能的拒付管理和收入追回解决方案之际。Amperos的代理能力提供端到端的拒付和收款自动化，同时一支主题专家团队为复杂且难以追回的索赔提供判断和专业知识支持。

Amperos then delivers detailed insights into how providers can optimize their billing and collections processes to prevent future denials. To date, Amperos has served over 3,000 clinical locations across all 50 states, driving nearly $700 million of revenue recovered per year across over 500,000 claims..

安培罗斯随后提供了关于供应商如何优化其计费和收款流程以防止未来拒绝的详细见解。迄今为止，安培罗斯已服务于全美50个州的3000多个临床地点，每年推动超过50万份索赔，挽回近7亿美元的收入。

“Complexity in healthcare revenue cycle management (RCM) should not be the norm, and that’s why our mission at Amperos is to streamline the denial and collections process so providers can focus on what matters most – operating their practices and serving their patients,” said Michal Miernowski, Co-Founder and CEO at Amperos Health.

“医疗保健收入周期管理（RCM）的复杂性不应成为常态，这就是为什么我们在Amperos的使命是简化拒绝和收款流程，以便供应商可以专注于最重要的事情——运营他们的诊所并服务患者，”Amperos Health的联合创始人兼首席执行官米哈尔·米埃尔诺夫斯基说道。

“I’m thrilled to announce our most recent funding round, which will be critical as Amperos accelerates its growth to serve more providers, expands its analytics capabilities, and launches new agentic capabilities in other RCM workflows.”.

“我很高兴地宣布我们最近的一轮融资，这将对Amperos加速增长、服务更多供应商、扩展其分析能力以及在其他RCM工作流程中推出新的代理功能起到至关重要的作用。”

Denials are rising in healthcare today, with

当前医疗保健领域的拒付情况正在增加，

12% of claims denied in 2024

2024年有12%的索赔被拒绝

, representing a

，代表一个

$262 billion

2620亿美元

loss in revenue to providers. Providers then spend more than

供应商的收入损失。然后供应商花费更多

$26 billion annually in recovering these denied claims, of which 70% end up getting paid

每年花费 260 亿美元来追回这些被拒绝的索赔，其中 70% 最终获得支付。

. And yet,

. 然而，

63% of RCM teams are understaffed

63% 的 RCM 团队人手不足

, while healthcare administration teams face a

，而医疗保健行政团队面临一个

32% annual turnover rate

32% 的年营业额

。

These statistics exemplify why Amperos has built a new product that can fill gaps in the RCM workforce while recovering more value in denied revenue. The product manages the full denial management process, from following up through insurance portals and calls to submitting corrected claims, medical records, and appeals..

这些统计数据说明了为什么 Amperos 开发了一款新产品，可以在填补 RCM（收入周期管理）劳动力缺口的同时，挽回更多被拒绝的收入。该产品管理整个拒付管理流程，从通过保险门户和电话跟进，到提交更正后的索赔、医疗记录和申诉。

“Denials are one of healthcare’s fastest-growing pain points: a growing portion of claims denied, hundreds of billions in lost revenue, and RCM teams that are chronically understaffed. It’s a broken process ripe for AI transformation,” said Sofia Guerra, Partner at Bessemer Venture Partners…

“拒付是医疗保健领域增长最快的痛点之一：被拒绝的索赔比例不断上升，数千亿美元的收入损失，以及长期人手不足的收入周期管理团队。这是一个亟需人工智能变革的破碎流程，”贝塞默风险投资公司的合伙人索菲亚·格雷拉表示……

Full release here

完整发布在这里

, originally announced April 22nd, 2026.

，最初宣布于2026年4月22日。